These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24841264)

  • 21. Pregnancy outcome after first trimester use of angiotensin AT1 receptor blockers: an observational cohort study.
    Hoeltzenbein M; Tissen-Diabaté T; Fietz AK; Zinke S; Kayser A; Meister R; Weber-Schoendorfer C; Schaefer C
    Clin Res Cardiol; 2018 Aug; 107(8):679-687. PubMed ID: 29574489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exposure to cox-2 inhibitors (coxibs) during the first trimester and pregnancy outcome: a prospective observational cohort study.
    Dathe K; Padberg S; Hultzsch S; Köhler LM; Meixner K; Fietz AK; Tissen-Diabaté T; Meister R; Schaefer C
    Eur J Clin Pharmacol; 2018 Apr; 74(4):489-495. PubMed ID: 29214381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pregnancy Outcomes Following Exposure to Quinolone Antibiotics - a Systematic-Review and Meta-Analysis.
    Ziv A; Masarwa R; Perlman A; Ziv D; Matok I
    Pharm Res; 2018 Mar; 35(5):109. PubMed ID: 29582196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study.
    Habermann F; Fritzsche J; Fuhlbrück F; Wacker E; Allignol A; Weber-Schoendorfer C; Meister R; Schaefer C
    J Clin Psychopharmacol; 2013 Aug; 33(4):453-62. PubMed ID: 23764684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study.
    Diav-Citrin O; Shechtman S; Ornoy S; Arnon J; Schaefer C; Garbis H; Clementi M; Ornoy A
    J Clin Psychiatry; 2005 Mar; 66(3):317-22. PubMed ID: 15766297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pregnancy outcome after first-trimester exposure to fosfomycin for the treatment of urinary tract infection: an observational cohort study.
    Philipps W; Fietz AK; Meixner K; Bluhmki T; Meister R; Schaefer C; Padberg S
    Infection; 2020 Feb; 48(1):57-64. PubMed ID: 31302868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones.
    Wogelius P; Nørgaard M; Gislum M; Pedersen L; Schønheyder HC; Sørensen HT
    Int J Antimicrob Agents; 2005 Oct; 26(4):323-6. PubMed ID: 16144758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: A systematic review and meta-analysis.
    Acar S; Keskin-Arslan E; Erol-Coskun H; Kaya-Temiz T; Kaplan YC
    Reprod Toxicol; 2019 Apr; 85():65-74. PubMed ID: 30738954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does the average drug exposure in pregnant women affect pregnancy outcome? A comparison of two approaches to estimate the baseline risks of adverse pregnancy outcome.
    Wacker E; Navarro A; Meister R; Padberg S; Weber-Schoendorfer C; Schaefer C
    Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):353-60. PubMed ID: 25644395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Birth Outcomes in Women Who Have Taken Hydroxycholoroquine During Pregnancy: A Prospective Cohort Study.
    Chambers CD; Johnson DL; Xu R; Luo Y; Felix R; Fine M; Lessard C; Adam MP; Braddock SR; Robinson LK; Burke L; Jones KL;
    Arthritis Rheumatol; 2022 Apr; 74(4):711-724. PubMed ID: 34725951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes.
    Djulus J; Koren G; Einarson TR; Wilton L; Shakir S; Diav-Citrin O; Kennedy D; Voyer Lavigne S; De Santis M; Einarson A
    J Clin Psychiatry; 2006 Aug; 67(8):1280-4. PubMed ID: 16965209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of major birth defects after first-trimester exposure to carbocisteine and ambroxol: A multicenter prospective cohort study using counseling data for drug safety during pregnancy.
    Usuda M; Jwa SC; Goto M; Kobayashi M; Nagano H; Yakuwa N; Yamane R; Murashima A; Makabe H
    Congenit Anom (Kyoto); 2024 May; 64(3):91-98. PubMed ID: 38445786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety of cetirizine during pregnancy. A prospective observational cohort study.
    Weber-Schoendorfer C; Schaefer C
    Reprod Toxicol; 2008 Sep; 26(1):19-23. PubMed ID: 18571373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy.
    Loureiro KD; Kao KK; Jones KL; Alvarado S; Chavez C; Dick L; Felix R; Johnson D; Chambers CD
    Am J Med Genet A; 2005 Jul; 136(2):117-21. PubMed ID: 15940677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.
    Thiel S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
    Mult Scler; 2016 May; 22(6):801-9. PubMed ID: 26920382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preliminary results on pregnancy outcomes in women using lamotrigine.
    Tennis P; Eldridge RR;
    Epilepsia; 2002 Oct; 43(10):1161-7. PubMed ID: 12366730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes.
    Bérard A; Zhao JP; Shui I; Colilla S
    Ann Rheum Dis; 2018 Apr; 77(4):500-509. PubMed ID: 29222350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011.
    Floridia M; Mastroiacovo P; Tamburrini E; Tibaldi C; Todros T; Crepaldi A; Sansone M; Fiscon M; Liuzzi G; Guerra B; Vimercati A; Vichi F; Vicini I; Pinnetti C; Marconi AM; Ravizza M;
    BJOG; 2013 Nov; 120(12):1466-75. PubMed ID: 23721372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Birth outcome following maternal use of fluoroquinolones.
    Larsen H; Nielsen GL; Schønheyder HC; Olesen C; Sørensen HT
    Int J Antimicrob Agents; 2001 Sep; 18(3):259-62. PubMed ID: 11673039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pregnancy outcomes following first-trimester exposure to topical retinoids: a systematic review and meta-analysis.
    Kaplan YC; Ozsarfati J; Etwel F; Nickel C; Nulman I; Koren G
    Br J Dermatol; 2015 Nov; 173(5):1132-41. PubMed ID: 26215715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.